H.C. Wainwright raised the firm’s price target on Ocular Therapeutix (OCUL) to $19 from $15 and keeps a Buy rating on the shares. The firm updated the company’s model with potential sales of Axpaxli in non-proliferative diabetic retinopathy.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Ocular Therapeutix price target raised to $31 from $21 at Piper Sandler
- Ocular Therapeutix price target raised to $24 from $17 at Baird
- Buy Rating for Ocular Therapeutix Driven by Strategic Advancements and Promising Clinical Trials in Diabetic Retinopathy
- Ocular Therapeutix: Buy Rating Affirmed Amid Promising Clinical Advancements and Strong Financial Position
- Ocular Therapeutix price target raised to $29 from $20 at Citizens JMP